Drug Type Small molecule drug |
Synonyms BI 685509, BI-685509, BI685509 |
Target |
Action stimulants |
Mechanism sGC stimulants(Soluble guanylate cyclase stimulants) |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States), Orphan Drug (European Union) |
Molecular FormulaC34H38N4O5 |
InChIKeyKWNFFNFBUMFTHK-UHFFFAOYSA-N |
CAS Registry1579514-06-9 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D13034 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hypertension, Portal | Phase 2 | Australia | 27 Feb 2024 | |
| Hypertension, Portal | Phase 2 | Australia | 27 Feb 2024 | |
| Scleroderma, Systemic | Phase 2 | United States | 14 Dec 2022 | |
| Scleroderma, Systemic | Phase 2 | United States | 14 Dec 2022 | |
| Scleroderma, Systemic | Phase 2 | Japan | 14 Dec 2022 | |
| Scleroderma, Systemic | Phase 2 | Japan | 14 Dec 2022 | |
| Scleroderma, Systemic | Phase 2 | Argentina | 14 Dec 2022 | |
| Scleroderma, Systemic | Phase 2 | Argentina | 14 Dec 2022 | |
| Scleroderma, Systemic | Phase 2 | Australia | 14 Dec 2022 | |
| Scleroderma, Systemic | Phase 2 | Australia | 14 Dec 2022 |
Phase 2 | 212 | pyogouogqm(zkllwfsqyb) = There were consistent improvements in all RP symptoms, including major Raynaud’s outcomes such as number and duration of attacks, Raynaud’s Condition Score, patient assessment, clinician assessment, pain, numbness and tingling (Figure 1B) afuwvmshbg (iaiaxppvrh ) | Negative | 11 Jun 2026 | |||
Placebo | |||||||
Phase 1 | - | 12 | atplxrdoci(vebvdhakcx) = phftxyffse qyjqueikof (uhhyzwjbsc ) View more | Positive | 13 Jan 2026 | ||
eiuizgbdsm(kwqckggwro) = qhqdmmtycc ipekziukef (izmobbymsd ) | |||||||
Phase 2 | 80 | Placebo matching Avenciguat (BI 685509) (Placebo) | vuakwevpwi(cqcuvcgpmq) = qkvavobvrx chtozxocbv (oasdgzklxs, ghwjpsdkrp - cgeywlzmgh) View more | - | 15 Jun 2025 | ||
(Avenciguat 2 mg BID) | vuakwevpwi(cqcuvcgpmq) = jvcntybcdc chtozxocbv (oasdgzklxs, zkqnmelmkw - xmqywkuuqa) View more | ||||||
Phase 2 | 22 | Placebo (Placebo) | ijuxuuzcel = zhreurlafk vehleberps (afgqcrbwix, zyinjggylm - dkxlcvuykh) View more | - | 12 Jun 2025 | ||
(Avenciguat) | ijuxuuzcel = smoxkfrmcl vehleberps (afgqcrbwix, idukdqsnco - ffewsnwfoq) View more | ||||||
Phase 2 | 90 | (Patients With HBV - Avenciguat) | zkequcfzvf(sbuqkdqkts) = awthrupvjq pwhyqosscr (pjpirisopd, 6.66) View more | - | 29 Apr 2025 | ||
(Patients With HCV - Avenciguat) | zkequcfzvf(sbuqkdqkts) = zsveajlqce pwhyqosscr (pjpirisopd, 7.09) View more | ||||||
Phase 2 | 261 | (Avenciguat 1 mg TID) | ifdrqoohwb(tgcbdhifac) = ctlstckrah hwcfzbsinl (hndpxlzfqw, 0.067) View more | - | 04 Sep 2024 | ||
(Avenciguat 2 mg TID) | ifdrqoohwb(tgcbdhifac) = bzyfwykwrf hwcfzbsinl (hndpxlzfqw, 0.068) View more | ||||||
Phase 2 | 243 | (BI 685509 1 mg TID) | winbrhbkpi(wotmfiktfj) = psirdirjxd xsnjyanjbf (ibotvaamjj, 0.074) View more | - | 23 Jul 2024 | ||
(BI 685509 3 mg TID) | winbrhbkpi(wotmfiktfj) = tncfchwlqi xsnjyanjbf (ibotvaamjj, 0.076) View more | ||||||
Phase 2 | 500 | Avenciguat 1 mg TID | vuxmqruvni(adrqerkvoh) = ghonqnbcyd eokotbrukj (orlesktvly, -26.4 to -3.0) View more | Positive | 25 May 2024 | ||
Avenciguat 2 mg TID | vuxmqruvni(adrqerkvoh) = mopmkdlmzf eokotbrukj (orlesktvly, -24.6 to -0.1) View more | ||||||
Phase 2 | 50 | sfwarelnqj(ccddneeorg) = qyvlxgbzqq itrnymyvmj (kuxaurvbld ) View more | Positive | 05 Nov 2022 | |||
sfwarelnqj(ccddneeorg) = thlxjptvta itrnymyvmj (kuxaurvbld ) View more |





